Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by A. Mateos.
Annals of Oncology | 2010
Maria-Dolores Chirlaque; Diego Salmerón; Eva Ardanaz; J. Galceran; R. Martínez; Rafael Marcos-Gragera; María José Sánchez; A. Mateos; A. Torrella; Riccardo Capocaccia; Carmen Navarro
BACKGROUND This study provides estimates of population-based relative survival in Spain for nine major cancers and reports results on cancer survival by region, gender and age group. PATIENTS AND METHODS Our analysis covered eight Spanish regions, namely, Basque Country, Navarre, Girona, Tarragona, Castellón, Albacete, Murcia and Granada, and included patients with cancer of the colon, rectum, lung, breast, ovary, prostate, testis, melanoma of skin and Hodgkins lymphoma. Cases diagnosed during the period 1995-99 were followed up until 31 December 2004. For individual records, the maximum likelihood approach was used to estimate 5-year relative survival (5y-RS), with crude and adjusted 5y-RS being calculated. A statistical test was applied to explain significant geographical variations. RESULTS In the regions studied, the highest 5y-RS ratio was detected for lung cancer (adjusted 5y-RS of 12.4% in Navarre versus 6.1% in Granada) and the lowest for breast cancer (91.3% in Castellón versus 81.2% in Albacete). 5y-RS for the respective cancer types was as follows: colon and rectal, 54.7% and 50.2%, respectively; ovarian, 43% overall, though much lower in the oldest age groups; prostate, 76%, rising to close to 80% in the 45-74 age group, with rates ranging from highest in Girona to lowest in Albacete; testicular, 95%, the type with the best prognosis; and Hodgkins lymphoma, 85%, rising to 92% among young adults. In the case of melanoma of skin, the sex-related difference in 5y-RS was >10% for women. CONCLUSIONS Although regional differences were identified for most tumours, these were more marked in lung cancer. Women showed better prognosis. Breast and prostate cancer registered lower survival among young than among middle-aged adults. The worst prognosis was for lung cancer and the best for cutaneous melanoma, with breast, prostate and Hodgkins lymphoma displaying favourable and colon, rectum and ovary unfavourable prognoses. Identifying regional, gender- and age-related differences affords valuable knowledge for improving cancer care.
Respiratory Medicine | 2012
Diego Salmerón; Maria-Dolores Chirlaque; M. Isabel Izarzugaza; María José Sánchez; R. Marcos-Gragera; Eva Ardanaz; J. Galceran; A. Mateos; Carmen Navarro
Survival in the case of lung cancer patients not only remains poor and decreases with advancing age at diagnosis, but recent European studies also report that it differs by sex. Our study sought to describe sex-related differences in lung cancer survival in Spain, and evaluate the role played by histologic type. Our analysis covered seven Spanish regions with population-based cancer registries. Cases diagnosed with lung cancer during the period 1995-1999 were followed up until December 31, 2004. To ascertain possible sex differences we performed multiple regression analysis. Age-standardized 5-year relative survival proved significantly higher in women (11.8%) than in men (9.2%), and among the youngest patients relative survival at 5 years conditional on surviving 1 year, was 1.74 times significantly higher in women than in men. The regression analysis showed that men had a higher relative excess risk of dying (RER) than did women (1.1 [95% CI 1.03-1.18]), with this being particularly marked among the 15-54 age group (1.42 [1.24-1.64]). Analysis by histologic type showed that in small cell carcinoma, men had a higher RER than women (1.29 [1.02-1.61]); in squamous cell carcinoma, men had a significantly lower RER than women during the first and fifth years; and in large cell carcinoma and adenocarcinoma, the RER displayed no significant sex-related differences. Lung cancer survival rates in Spain are poor, with better prognosis in women, especially among patients aged under 55 years at diagnosis, or those with small cell carcinoma.
Clinical & Translational Oncology | 2018
Maria-Dolores Chirlaque; Diego Salmerón; J. Galceran; A. Ameijide; A. Mateos; A. Torrella; R. Jiménez; Nerea Larrañaga; Rafael Marcos-Gragera; Eva Ardanaz; Milena Sant; Pamela Minicozzi; Carmen Navarro; María José Sánchez
Clinical & Translational Oncology | 2017
Rafael Marcos-Gragera; J. Galceran; Carmen Martos; A. L. de Munain; M. Vicente-Raneda; Carmen Navarro; J. R. Quirós-Garcia; María José Sánchez; Eva Ardanaz; M.A. Ramos; A. Mateos; Diego Salmerón; S. Felipe; R. Peris-Bonet
Clinical & Translational Oncology | 2018
Rafael Marcos-Gragera; M. Solans; J. Galceran; R. Fernández-Delgado; A. Fernández-Teijeiro; A. Mateos; J. R. Quirós-Garcia; N. Fuster-Camarena; V. De Castro; María José Sánchez; P. Franch; Maria-Dolores Chirlaque; Eva Ardanaz; Carmen Martos; Diego Salmerón; R. Peris-Bonet